Mesoblast Limited (NASDAQ:MESO - Get Free Report)'s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $10.89, but opened at $12.00. Mesoblast shares last traded at $12.27, with a volume of 116,957 shares trading hands.
Analysts Set New Price Targets
Separately, Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
View Our Latest Stock Report on MESO
Mesoblast Stock Up 11.3%
The company has a quick ratio of 0.63, a current ratio of 0.96 and a debt-to-equity ratio of 0.22. The stock has a 50 day moving average price of $11.33 and a two-hundred day moving average price of $14.04.
Institutional Investors Weigh In On Mesoblast
A number of institutional investors have recently modified their holdings of MESO. Bank of America Corp DE grew its stake in shares of Mesoblast by 1,503.3% in the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after buying an additional 272,595 shares in the last quarter. Goldman Sachs Group Inc. acquired a new position in Mesoblast during the 1st quarter worth $3,209,000. Oaktree Capital Management LP acquired a new position in Mesoblast during the 4th quarter worth $3,556,000. GAMMA Investing LLC grew its stake in Mesoblast by 1,174.2% during the 1st quarter. GAMMA Investing LLC now owns 85,513 shares of the company's stock worth $1,067,000 after purchasing an additional 78,802 shares in the last quarter. Finally, Summit X LLC grew its stake in Mesoblast by 36.0% during the 1st quarter. Summit X LLC now owns 198,163 shares of the company's stock worth $2,473,000 after purchasing an additional 52,508 shares in the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
